SE468231B - Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos - Google Patents

Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos

Info

Publication number
SE468231B
SE468231B SE8402702A SE8402702A SE468231B SE 468231 B SE468231 B SE 468231B SE 8402702 A SE8402702 A SE 8402702A SE 8402702 A SE8402702 A SE 8402702A SE 468231 B SE468231 B SE 468231B
Authority
SE
Sweden
Prior art keywords
methanol
fuk
antigen
tissue
chloroform
Prior art date
Application number
SE8402702A
Other languages
English (en)
Swedish (sv)
Other versions
SE8402702D0 (sv
SE8402702L (sv
Inventor
J R Holmgren
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE8402702A priority Critical patent/SE468231B/sv
Publication of SE8402702D0 publication Critical patent/SE8402702D0/xx
Priority to EP85850172A priority patent/EP0162825B1/de
Priority to DE8585850172T priority patent/DE3582191D1/de
Priority to AT85850172T priority patent/ATE61734T1/de
Priority to JP60105729A priority patent/JPS6193A/ja
Publication of SE8402702L publication Critical patent/SE8402702L/xx
Priority to US07/123,377 priority patent/US4888275A/en
Publication of SE468231B publication Critical patent/SE468231B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
SE8402702A 1984-05-18 1984-05-18 Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos SE468231B (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE8402702A SE468231B (sv) 1984-05-18 1984-05-18 Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos
EP85850172A EP0162825B1 (de) 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen)
DE8585850172T DE3582191D1 (de) 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
AT85850172T ATE61734T1 (de) 1984-05-18 1985-05-15 Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
JP60105729A JPS6193A (ja) 1984-05-18 1985-05-17 特異性がん関連抗原、フコシルシアロシルガングリオテトラオースおよびヒトの肺がんに関連する診断または治療処置におけるその使用
US07/123,377 US4888275A (en) 1984-05-18 1987-11-20 Diagnosing and monitoring cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8402702A SE468231B (sv) 1984-05-18 1984-05-18 Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos

Publications (3)

Publication Number Publication Date
SE8402702D0 SE8402702D0 (sv) 1984-05-18
SE8402702L SE8402702L (sv) 1985-11-19
SE468231B true SE468231B (sv) 1992-11-23

Family

ID=20355939

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8402702A SE468231B (sv) 1984-05-18 1984-05-18 Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos

Country Status (6)

Country Link
US (1) US4888275A (de)
EP (1) EP0162825B1 (de)
JP (1) JPS6193A (de)
AT (1) ATE61734T1 (de)
DE (1) DE3582191D1 (de)
SE (1) SE468231B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57194876A (en) * 1981-05-21 1982-11-30 Seiko Seiki Co Ltd Controlling method of grinding machine
US5122450A (en) * 1985-10-24 1992-06-16 Research Corporation Limited Biochemical reagent
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
US5545532A (en) * 1993-02-05 1996-08-13 Epigen, Inc. Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging
EP2239582A1 (de) * 2009-04-09 2010-10-13 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Testsystem zur Bestimmung der Bindung an hydrophobe Arzneimittel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3202894A1 (de) * 1982-01-29 1983-08-11 Otsuka Pharmaceutical Co. Ltd., Tokyo Verfahren zur bestimmung von tumor-assoziierten glykoprotein enthaltenden verbindungen, anwendung des verfahrens zur krebsdiagnose und kit fuer die anwendung des verfahrens
EP0111005B1 (de) * 1982-06-03 1988-04-20 Otsuka Pharmaceutical Co., Ltd. Fucose-Antigene, Verfahren zu ihrer Herstellung und gegen diese gerichtete Antikörper, Testeinheit, enthaltend das Fucose Antigen und ein Verfahren zur Bestimmung von tumorassoziierten Zuckerketten
DK463283A (da) * 1982-10-08 1984-04-09 Otsuka Pharma Co Ltd Glycosidbinding-relateret antigen, fremgangsmaade til fremstilling heraf og anticancermiddel indeholdende dette antigen som aktiv komponent
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
JPS6057254A (ja) * 1983-09-09 1985-04-03 Dainabotsuto Kk 免疫学的測定法による糖脂質の定量方法

Also Published As

Publication number Publication date
SE8402702D0 (sv) 1984-05-18
EP0162825A2 (de) 1985-11-27
EP0162825A3 (en) 1987-10-07
DE3582191D1 (de) 1991-04-25
JPS6193A (ja) 1986-01-06
SE8402702L (sv) 1985-11-19
ATE61734T1 (de) 1991-04-15
US4888275A (en) 1989-12-19
EP0162825B1 (de) 1991-03-20

Similar Documents

Publication Publication Date Title
Fredman et al. Monoclonal antibody A2B5 reacts with many gangliosides in neuronal tissue
Lemieux et al. Artificial antigens. Antibody preparations for the localization of Lewis determinants in tissues
US5240833A (en) Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
Ratcliffe et al. Synthesis of the T [β-D-Gal-(1→ 3)-α-D-GalNAc]-antigenic determinant in a form useful for the preparation of an effective artificial antigen and the corresponding immunoadsorbent
JPS62190074A (ja) ヒトの癌に付随したジフコガングリオシドを規定するハイブリド−マ抗体
Westman et al. Identification of the molecular and genetic basis of PX2, a glycosphingolipid blood group antigen lacking on globoside-deficient erythrocytes
NO853397L (no) Nye monoklonale antistoffer til glykokonjugater, fremgangsmaate til fremstilling derav og anvendelser av antistoffene.
EP0173663B1 (de) Verwendung eines spezifischen tumorassoziierten Antigens, Sialosyllactotetraose, in Diagnose- oder Therapieverfahren bezüglich Krebskrankheiten
NO830404L (no) Paavisning av maligne tumor-celler.
JPS6057254A (ja) 免疫学的測定法による糖脂質の定量方法
EP0162825B1 (de) Verwendung eines spezifischen karzinomassoziierenden Antigens (Hapten), Fucosylsialosylgangliotetrose (Fuc-GM1) in diagnostischen und therapeutischen Verfahren betreffend den menschlichen Lungenkrebs (Carcinomas von kleinen Zellen)
US5827828A (en) Sulfated glycolipids and antibodies thereto for prophylaxis or therapy of diabetes
PT92235B (pt) Processo para a preparacao de um anticorpo monoclonal anti-fucosilceramida e de agentes de diagnostico que o contem
Kundu et al. Aminopropyl silica gel as a solid support for preparation of glycolipid immunoadsorbent and purification of antibodies.
DE69008178T2 (de) Analyse von vitamin b12.
JP3286845B2 (ja) Ｇｍ２特異的抗体の製造方法
Judd et al. An Anti‐B Reagent Prepared from the α‐D‐Galactopyranosyl‐Binding Isolectins from Bandeiraea Simplicifolia Seeds
DE3785175T2 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
EP0293940B1 (de) Monoklonal-Antikörper und Methode für die Bereitung von Hybridoma, produzierend diese Antikörper
EP0106285A2 (de) Glycosidische Verbindung bezüglich Antigen, Verfahren zur Herstellung und diese enthaltende Antikrebsmittel
CN118620016B (zh) 一种仿刺参海参皂苷半抗原、人工抗原、抗体及其制备方法和应用
Pendu et al. Expression of ABH, Lewis and related tissue antigens in the human thymus
EP0386140A1 (de) Essentielle hypertension assozierte faktoren
EP0051593A1 (de) Isolierung von kohlehydraten aus zellgeweben
JPS6317698A (ja) モノクロ−ナル抗体ｔｓ−１およびトリフコシル−ｎ−アセチルラクトサミン糖誘導体

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8402702-8

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8402702-8

Format of ref document f/p: F